• 中国精品科技期刊
  • 《中文核心期刊要目总览》收录期刊
  • RCCSE 中国核心期刊(5/114,A+)
  • Scopus收录期刊
  • 美国《化学文摘》(CA)收录期刊
  • WHO 西太平洋地区医学索引(WPRIM)收录期刊
  • 《中国科学引文数据库(CSCD)》核心库期刊 (C)
  • 中国科技核心期刊
  • 中国科技论文统计源期刊
  • 《日本科学技术振兴机构数据库(中国)》(JSTChina)收录期刊
  • 美国《乌利希期刊指南》(UIrichsweb)收录期刊
  • 中华预防医学会系列杂志优秀期刊(2019年)

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

河南省新型冠状病毒Omicron变异株感染者临床症状影响因素分析

潘静静,  范威,  李亚飞,  于铭洋,  王莹莹,  王文华,  王若琳,  尤爱国,  聂轶飞,  王海峰,  叶莹,  黄学勇,  郭万申

downloadPDF
文章导航 > 中华疾病控制杂志  > 2023 >  27(3): 326-328
潘静静, 范威, 李亚飞, 于铭洋, 王莹莹, 王文华, 王若琳, 尤爱国, 聂轶飞, 王海峰, 叶莹, 黄学勇, 郭万申. 河南省新型冠状病毒Omicron变异株感染者临床症状影响因素分析[J]. 中华疾病控制杂志, 2023, 27(3): 326-328. doi: 10.16462/j.cnki.zhjbkz.2023.03.014
引用本文: 潘静静, 范威, 李亚飞, 于铭洋, 王莹莹, 王文华, 王若琳, 尤爱国, 聂轶飞, 王海峰, 叶莹, 黄学勇, 郭万申. 河南省新型冠状病毒Omicron变异株感染者临床症状影响因素分析[J]. 中华疾病控制杂志, 2023, 27(3): 326-328. doi: 10.16462/j.cnki.zhjbkz.2023.03.014
shu
PAN Jing-jing, FAN Wei, LI Ya-fei, YU Ming-yang, WANG Ying-ying, WANG Wen-hua, WANG Ruo-lin, YOU Ai-guo, NIE Yi-fei, WANG Hai-feng, YE Ying, HUANG Xue-yong, GUO Wan-shen. Analysis on the influencing factors for COVID-19 Omicron variant cases' clinical symptoms in Henan Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2023, 27(3): 326-328. doi: 10.16462/j.cnki.zhjbkz.2023.03.014
Citation: PAN Jing-jing, FAN Wei, LI Ya-fei, YU Ming-yang, WANG Ying-ying, WANG Wen-hua, WANG Ruo-lin, YOU Ai-guo, NIE Yi-fei, WANG Hai-feng, YE Ying, HUANG Xue-yong, GUO Wan-shen. Analysis on the influencing factors for COVID-19 Omicron variant cases' clinical symptoms in Henan Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2023, 27(3): 326-328. doi: 10.16462/j.cnki.zhjbkz.2023.03.014
shu

河南省新型冠状病毒Omicron变异株感染者临床症状影响因素分析

doi: 10.16462/j.cnki.zhjbkz.2023.03.014

  • 450016 郑州，河南省疾病预防控制中心传染病预防控制所

基金项目: 

河南省医学科技攻关计划省部共建项目 SBGJ202001003

河南省科技厅重大专项 211100311000

河南省医学科技攻关计划联合共建项目 LHGJ20210144

河南省中青年卫生健康科技创新领军人才培训项目 YXKC2020006

详细信息
    通讯作者:

    郭万申，E-mail：gwscdc@126.com

  • 中图分类号: R183.3

Analysis on the influencing factors for COVID-19 Omicron variant cases' clinical symptoms in Henan Province

  • Institute for Infectious Disease Prevention and Control, Henan Province Center for Disease Control and Prevention, Zhengzhou 450016, China

Funds: 

Joint Construction Project of Henan Medical Science and Technology Project SBGJ202001003

Major Special Project of the Department of Science and Technology in Henan Province 211100311000

Joint Construction Project of Henan Medical Science and Technology Project LHGJ20210144

Health Science and Technology Innovation of Young and Middle-aged Personnel Training Project in Henan Province YXKC2020006

More Information

    摘要
  • 摘要:   目的  分析河南省新型冠状病毒Omicron变异株感染者临床症状的影响因素，指导疫情防控。  方法  将河南省安阳市2022年1月本土Omicron感染者作为研究对象，收集其流行病学调查、实验室检测等信息，采用描述流行病学方法进行分析。  结果  共报告468例感染者，其中重型2例(0.4%)，无死亡病例，具有临床症状的90例(19.2%)；38例(8.1%)未接种或未全程接种新型冠状病毒(简称新冠)疫苗，92例(19.7%)完成全程接种新冠疫苗超过6个月(含完成加强接种在28 d内)，338例(72.2%)完成全程接种新冠疫苗在6个月内或完成加强接种超过28 d。有症状的病例中女性构成比高于男性(χ2=4.270，P=0.039)；全程接种在6个月内的比例低于无症状的病例(χ2=9.882，P=0.007)。多因素logistic回归分析模型分析结果显示，全程接种在6个月内及完成加强接种超过28 d是出现症状的保护因素(OR=0.455, 95% CI: 0.212~0.978, P=0.044)。  结论  对于Omicron，全程接种新冠疫苗在6个月内及加强接种可以减少或减轻症状，应持续推进疫苗接种工作。
    Abstract:   Objective  To analyze the influencing factors for COVID-19 Omicron variant cases' clinical symptoms in Henan Province, so as to guide epidemic prevention and control.  Methods  Local Omicron variant cases in Anyang City, Henan Province in January, 2022, were selected as the study subjects. Epidemiological investigation and laboratory testing result were collected, and statistical descriptive analysis was conducted.  Results  A total of 468 cases of infection were reported, including 2 severe cases (0.4%). No death cases was reported. Among them, 90 cases (19.2%) had clinical symptoms, 38 cases (8.1%) were not vaccinated or did not receive full vaccination, 92 cases (19.7%) completed full vaccination for more than 6 months (including booster vaccination within 28 days), and 338 cases (72.2%) completed full vaccination within 6 months or booster vaccination for more than 28 days. In the patients with symptoms, the proportion of female was higher than that of male patients (χ2=4.270, P=0.039), and the proportion of completed full vaccination within 6 months or booster vaccination for more than 28 days was lower than that of asymptomatic cases (χ2=9.882, P=0.007). Multivariate logistic regression analysis showed that less than 6 months after full vaccination and more than 28 days after intensive vaccination were protective factors for symptoms (OR=0.455, 95% CI: 0.212-0.978, P=0.044).  Conclusions  For Omicron variant strains, full vaccination within 6 months and booster vaccination can reduce or alleviate symptoms.Vaccination should be continued.
    • HTML全文

  • 表  1  感染者有临床症状和无临床症状特征比较[n(%)]

    Table  1.   Comparison of characteristics of symptomatic and asymptomatic cases[n(%)]

    基本情况 有症状 无症状 合计 χ2/Z值 P值
    性别 4.270 0.039
      男 29(32.2) 167(44.2) 196(41.9)
      女 61(67.8) 211(55.8) 272(58.1)
    年龄[M(P25, P75), 岁] 18(17, 35) 18(17, 34) 18(17, 34) -0.243 a 0.808
    基础性疾病 0.546
      有 2(2.2) 16(4.2) 18(3.8)
      无 88(97.8) 362(95.8) 450(96.2)
    暴露频率 0.054
      经常 57(91.9) 214(85.6) 271(86.9)
      一般 0(0.0) 19(7.6) 19(6.1)
      偶尔 5(8.1) 17(6.8) 22(7.1)
    暴露时段 0.767
      非危险时段 3(7.7) 15(11.4) 18(10.5)
      危险时段 36(92.3) 117(88.6) 153(89.5)
    疫苗接种情况 9.882 0.007
      未接种或未全程接种 11(12.2) 27(7.1) 38(8.1)
      全程接种超过6个月(含加强接种在28 d内) 26(28.9) 66(17.5) 92(19.7)
      全程接种在6个月内及完成加强接种超过28 d 53(58.9) 285(75.4) 338(72.2)
    注：a Z检验。
    下载: 导出CSV

    表  2  感染者是否出现临床症状影响因素的多因素分析

    Table  2.   Multivariate analysis of influencing factors for clinical symptoms

    分析变量和参照组 OR(95% CI)值 P值
    性别：女性=1，男性=0 1.630(0.997~2.664) 0.051
    全程接种超过6个月(含加强接种在28 d内)=1，未接种或未全程接种=0 0.943(0.407~2.185) 0.891
    全程接种在6个月内及完成加强接种超过28 d=2，未接种或未全程接种=0 0.455(0.212~0.978) 0.044
    常数项 0.186 0.002
    下载: 导出CSV
    • 参考文献(8)
  • [1] World Health Organization. Listings of WHO's response to COVID-19[EB/OL]. (2020-06-29)[2022-01-09]. https://www.who.int/news/item/29-06-2020-covidtimeline.
    [2] World Health Organization. Classification of Omicron (B. 1.1.529): SARS-CoV-2 variant of concern[EB/OL]. (2021-11-26)[2022-01-09]. Classification of Omicron (B. 1.1.529): SARS-CoV-2 Variant of Concern (who. int).
    [3] World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 6 January 2022. Geneva: World Health Organization; 2022[EB/OL]. (2022-01-06)[2022-01-09]. https://www.who.int/multi-media/details/who-press-conference-on-coronavirus-disease-(COVID-19)-6-January-2022.
    [4] Ren SY, Wang WB, Gao RD, et al. Omicron variant (B. 1.1.529) of SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance[J]. World J Clin Cases. 2022, 10(1): 1-11. DOI: 10.12998/wjcc.v10.i1.1.
    [5] 国务院应对新型冠状病毒肺炎疫情联防联控机制综合组. 新型冠状病毒肺炎防控方案(第八版)[EB/OL]. (2021-05-14)[2021-12-21]. http://www.nhc.gov.cn/jkj/s3577/202105/6f1e8ec6c4a540d99fafef52fc86d0f8.shtml.

    State Council Joint Prevention and Control Mechanism Against COVID-19. Protocol for prevention and control of COVID-19 (edition 8)[EB/OL]. (2021-05-14)[2021-12-21]. http://www.nhc.gov.cn/jkj/s3577/202105/6f1e8ec6c4a540d99fafef52fc86d0f8.shtml.
    [6] Kim MK, Lee B, Choi YY, et al. Clinical characteristics of 40 patients infected with the SARS-CoV-2 Omicron Variant in Korea. J Korean[J]. 2022, 37(3): e31. DOI: 10.3346/jkms.2022.37.e31.
    [7] Maisa A, Spaccaferri G, Fournier L, et al. First cases of Omicron in France are exhibiting mild symptoms, November 2021-January 2022[J]. Infect Dis Now, 2022, 52(3): 160-164. DOI: 10.1016/j.idnow.2022.02.003.
    [8] Abdullah F, Myers J, Basu D, et al. Decreased severity of disease during the first global Omicron variant covid-19 outbreak in a large hospital in tshwane, south Africa[J]. Int J Infect Dis. 2021, 116: 38-42. DOI: 10.1016/j.ijid.2021.12.357.
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
表(2)
计量
  • 文章访问数:  202
  • HTML全文浏览量:  109
  • PDF下载量:  40
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-03-16
  • 修回日期:  2022-06-04
  • 网络出版日期:  2023-04-04
  • 刊出日期:  2023-03-10

目录

    /

    返回文章
    返回

    版权所有 © 《中华疾病控制杂志》编辑部 皖ICP备05003562号

    本系统由 北京仁和汇智信息技术有限公司 开发